EUCTR2005-001188-70-LT进行中（未招募）不适用
A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg QD and 90 mg QD) and an Active Comparator, Lansoprazole (30 mgQD) on Healing of Erosive Esophagitis
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,950
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Prior to any study-specific procedures being performed, the subject voluntarily signs an Informed Consent Form (ICF)/and any privacy statement/authorization form required by the region in which the subject is participating, after having its contents fully explained and all questions answered. An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) must approve the ICFs.
- •2. Male or female subjects at least 18 years of age (and of legal age of consent).
- •3. All female subjects must have a negative serum pregnancy test at Screening and negative urine pregnancy test at Day -1 and are using, and agree to continued use of, a double barrier method of birth control. Oral, injectable or patch contraceptives may be used as one method if the subject has been taking them for greater than three months duration at the Screening Visit. Subjects who have had a bilateral tubal ligation, hysterectomy or are post-menopausal (the absence of menses for 1-2 years with a Follicle-Stimulating Hormone [FSH] level ? 40 IU/L or absence of menses for > 2 years) are not required to use birth control.
- •4. Subject must have endoscopically confirmed EE as defined by the Los Angeles (LA) Classification Grading System (A-D).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subject tests positive for H pylori based on the result of the CLO test. In the U.S. and Canada, a CLO test will only be performed for those subjects who test positive for H pylori by finger stick or serology at screening and have EE. For all other countries, a mandatory CLO test will be used at screening to determine subjects H pylori status
- •2. Use of prescription or non-prescription proton pump inhibitors (PPIs) during screening and throughout the study.
- •3. Use of prescription or non-prescription histamine (H2) receptor antagonists or sucralfate during screening and throughout the study.
- •4. Chronic use (>12 doses per month) of non-steroidal anti-inflammatory drugs (NSAIDs) including COX 2 NSAIDs within 30 days prior to the Screening Period and throughout the study, however, low dose aspirin up to 325 mg per day is allowed.
- •5. Use of antacids [except for study supplied Gelusil® (U.S. sites), or a similar equivalent approved antacid (ex U.S. sites)] during the Screening and Treatment Periods.
- •6. Subjects using drugs with significant anticholinergic effects such as tricyclics who cannot stay on a stable dose for the 4 weeks prior to dosing and throughout the study.
- •7. Subjects who cannot discontinue the use of the following medications prior to the first dose of study drug and throughout the study: misoprostol prokinetics
- •8. Need for continuous anticoagulant therapy.
- •9. Use of any investigational drug(s) within 30 days of Screening.
- •10. Cancer (except basal cell carcinoma of the skin) within 3 years prior to Screening.
- •11. Any condition that may require inpatient surgery during the course of the study.
- •12. Endoscopic Barrett’s esophagus and/or definite dysplastic changes in the esophagus. If any suspicious Barrett’s esophagus is seen during screening and the principal investigator is confident that the subject will be confirmed with Barrett’s, the subject may be automatically excluded. Otherwise, any suspicious Barrett’s esophagus seen during screening endoscopy will be biopsied and sent to a local pathology laboratory. Subjects may be randomized; however, the subject must be discontinued if the Screening biopsy is found to confirm Barrett’s and/or to have definite dysplastic changes. If the subject is discontinued, Final Visit procedures must be performed, with the exception of the endoscopy. Subjects with indeterminate dysplasia due to severe inflammation may be enrolled and rebiopsied at the next endoscopy.
- •13. Subjects with a history of dilatation of esophageal strictures, other than a Schatzki’s ring (a ring of mucosal tissue near the lower esophageal sphincter).
- •14. Subjects with active gastric or duodenal ulcers within 4 weeks of the first dose of study drug.
- •15. Co-existing diseases affecting the esophagus (eg, esophageal varices, scleroderma, viral, fungal infection or esophageal stricture), history of radiation therapy or cryotherapy to the esophagus, caustic or physiochemical trauma such as sclerotherapy to the esophagus.
- •16. Evidence of uncontrolled systemic disease.
- •17. Subject has abnormal laboratory values that suggest a clinically significant underlying disease or condition that may prevent the subject from entering the study or subject with the following lab abnormalities: Creatinine >1.5 mg/dL, Alanine Aminotransferase (ALT) and /or Aspartate Aminotransferase (AST) >2.5X the upper limits of normal, or Bilirubin >2.0 mg/dl with AST/ALT elevated above normal values.
- •18. Subject known
研究者
相似试验
进行中（未招募）
不适用
A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg QD and 90 mg QD) and an Active Comparator, Lansoprazole (30 mgQD) on Healing of Erosive EsophagitisErosive esophagitisEUCTR2005-001187-31-LTTAP Pharmaceutical Products Inc.1,950
进行中（未招募）
不适用
A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg QD and 90 mg QD) and an Active Comparator, Lansoprazole (30 mgQD) on Healing of Erosive EsophagitisErosive esophagitisEUCTR2005-001187-31-HUTAP Pharmaceutical Products Inc.1,950
进行中（未招募）
不适用
A Study to Test the Effect and Safety of Brodalumab Compared With Placebo and Ustekinumab and the Results of Changing Strength or Frequency of Brodalumab in People with Moderate to Severe Plaque Psoriasis: AMAGINE-3Moderate to severe plaque psoriasisMedDRA version: 14.1Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2012-000667-24-LVAmgen Inc.1,800
进行中（未招募）
不适用
A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects with Healed Erosive EsophagitisErosive esophagitisEUCTR2005-001190-10-LVTAP Pharmaceutical Products Inc.1,950
进行中（未招募）
不适用
A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects with Healed Erosive EsophagitisErosive esophagitisEUCTR2005-001190-10-LTTAP Pharmaceutical Products Inc.360